Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Acer Therapeutics Inc. ACER
$0.75
-$0 (-0.61%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
18072319.00000000
-
week52high
4.56
-
week52low
0.65
-
Revenue
0
-
P/E TTM
0
-
Beta
0.57370200
-
EPS
-1.59000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 20:01
Описание компании
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| EF Hutton | Buy | 02 февр 2022 г. | |
| Needham | Hold | Buy | 25 июн 2019 г. |
| Wedbush | Outperform | 23 мая 2019 г. | |
| Needham | Buy | 20 дек 2018 г. | |
| Raymond James | Strong Buy | Outperform | 17 авг 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ASELAGE STEVE | A | 483741 | 409836 | 29 ноя 2022 г. |
| Schelling Chris | A | 2712529 | 819672 | 29 ноя 2022 г. |
| Hayden Tanya | A | 25000 | 25000 | 19 июн 2022 г. |
| Quartel Adrian W | A | 200000 | 200000 | 21 февр 2022 г. |
| Paul Bernard H | A | 25000 | 25000 | 14 янв 2022 г. |
| Seibt Matthew | A | 25000 | 25000 | 14 янв 2022 г. |
| PALMIN HARRY S | A | 25000 | 25000 | 14 янв 2022 г. |
| Schelling Chris | A | 50000 | 50000 | 14 янв 2022 г. |
| Klopp John Michael | A | 25000 | 25000 | 14 янв 2022 г. |
| Joseph Donald | A | 25000 | 25000 | 14 янв 2022 г. |
Новостная лента
ACER's Stock Down on Failure of Phase II Study, Cash Updates
Zacks Investment Research
20 мар 2023 г. в 13:46
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
7 Penny Stocks With Strong Insider Buying Signals
InvestorPlace
05 мар 2023 г. в 12:10
When it comes to penny stocks, a diligent look at fundamentals and insider activity should be key to your research. After all, penny stocks with strong insider buying can potentially be strong opportunities.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Zacks Investment Research
18 янв 2023 г. в 10:33
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
Zacks Investment Research
16 янв 2023 г. в 11:17
Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
Zacks Investment Research
29 дек 2022 г. в 11:17
Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.